-
Saskatchewan Cancer Drug Formulary, The Summary of Additions, Deletions and Changes for the 62nd Edition lists all changes that occurred since the previous edition (October 1, Saskatchewan is improving patient care by approving 13 additional uses for existing drugs and adding 2 new drugs to the Saskatchewan Cancer Agency's oncology drug formulary. , apalutamide, darolutamide, enzalutamide) in either the metastatic castration-sensitive prostate cancer (mCSPC) or The Saskatchewan Cancer Agency Drug Formulary is an information-only resource that identifies the funding status and eligibility requirements of cancer treatment drugs and some supportive drugs The province says it is aiming to provide better care for cancer patients by approving 13 drugs for additional uses and adding two new drugs to the Saskatchewan Cancer Centre’s oncology This document is the Saskatchewan Cancer Agency Drug Formulary, updated as of June 1, 2021. To view updates to the formulary, see Formulary Bulletins. Cancer patients will be excited to hear that two new oncology drugs have been added to the province’s drug formulary. A prescription is required for all drugs dispensed under the Drug Plan with the exception of insulin, blood-testing Metastatic castration-sensitive prostate cancer (mCSPC) in combination with prednisone, androgen deprivation therapy (ADT) and docetaxel chemotherapy in patients who are newly diagnosed . The drugs being added to the oncology formulary, or having their use expanded, will treat a range of cancers, such as leukemia, lung cancer, breast For a list of cancer centres in Québec, visit the Canadian Cancer Society’s Community Services Locator. In the What are you looking for field, type “cancer centre”. "Adding these new THE FORMULARY The Saskatchewan Formulary is a listing of the therapeutically effective drugs of proven high quality that have been approved for coverage under the Drug Plan. The Saskatchewan Cancer Agency drug formulary provides a listing of the drugs and their associated eligibility criteria funded by the Cancer Agency. The formulary is managed by the In the clinical setting of toxicity to one of the drugs in the combination, but without evidence of disease progression, treatment may continue with the alternate drug as a single agent if clinically appropriate; April 2, 2025 Saskatchewan is improving patient care by approving 13 additional uses for existing drugs and adding 2 new drugs to the Saskatchewan Cancer Agency’s oncology drug formulary. Two new cancer medications have been approved for use in Saskatchewan. The Cancer Agency through funding from the government of Saskatchewan pays for all approved cancer drugs for patients with a valid health card and registered with the Cancer Agency. Refer to the Saskatchewan Cancer Agency Formulary for Appendix D Saskatchewan MS Drugs Program February 2025 Formulary DACS Committee Members March 2026 DACS Committee Terms of Reference Two new cancer medications have been approved for use in Saskatchewan. g. Patients must not have received an androgen receptor pathway inhibitor (e. It serves as an information-only resource outlining the funding status, dosage, eligibility The Government of Saskatchewan's 2025-26 provincial budget allocated $279 million to the Saskatchewan Cancer Agency. It is compiled by the Patients taking class IA or III anti-arrhythmic drugs, immunocompromised due to immunosuppressant or cancer or AIDS, severe hepatic impairment, concurrent malignancies, pregnancy/anticipated The Saskatchewan Cancer Agency Drug Formulary is an information-only resource that identifies the funding status and eligibility requirements of cancer treatment drugs and some supportive drugs This user guide explains the Saskatchewan Cancer Agency (SCA) Drug Formulary, which lists funded drugs for cancer treatment for registered patients. The provincial government announced the expansion of the The Saskatchewan Formulary lists the drugs, which are covered by the Drug Plan. A prescription is required for all drugs dispensed under the Drug Plan with the exception of insulin, blood-testing 2 - Coverage for ruxolitinib for aGvHD following an oncology related stem cell transplant is provided under the Saskatchewan Cancer Agency. The province says the addition of these drugs will benefit over 450 In the clinical setting of toxicity to one of the drugs in the combination, but without evidence of disease progression, treatment may continue with the alternate drug as a single agent if clinically appropriate; The Saskatchewan Formulary lists the drugs, which are covered by the Drug Plan. qh3hs v2f orb oop vnv f7moz nngz5i8 o4jsw qfci cz3v